PB-22 (QUPIC,SGT-21 or1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester) is adesigner drug offered by online vendors as a cannabimimetic agent, and detected being sold insynthetic cannabis products in Japan in 2013.[1][2] PB-22 represents a structurally unique synthetic cannabinoid chemotype, since it contains an ester linker at the indole 3-position, rather than the precedented ketone ofJWH-018 and itsanalogs, or the amide ofAPICA and its analogs.
PB-22 has anEC50 of 5.1 nM for human CB1 receptors, and 37 nM for human CB2 receptors.[3] PB-22 producesbradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, suggesting potent cannabinoid-like activity.[3] The magnitude and duration of hypothermia induced in rats by PB-22 was notably greater thanJWH-018,AM-2201,UR-144,XLR-11,APICA, orSTS-135, with a reduction of body temperature still observable six hours after dosing.[3] One clinical toxicology study found PB-22 to be the cause of seizures in a human and his dog.[4]
PB-22 was originally developed by New Zealand legal highs companyStargate International in 2012 as SGT-21, intended to be a structural hybrid ofQMPSB andJWH-018.[5] However, no intellectual property protection was applied for and the compound quickly became subject to widespread grey-market sales outside the control of the inventors.
^Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2013). "Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products".Forensic Toxicology.31 (2):223–240.doi:10.1007/s11419-013-0182-9.S2CID1279637.
^Gugelmann H, Gerona R, Li C, Tsutaoka B, Olson KR, Lung D (July 2014). "'Crazy Monkey' poisons man and dog: Human and canine seizures due to PB-22, a novel synthetic cannabinoid".Clinical Toxicology.52 (6):635–638.doi:10.3109/15563650.2014.925562.PMID24905571.S2CID207647659.
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived fromthe original on 1 October 2015. Retrieved1 October 2015.
